Ask Dr James: What can I do about my restless legs?
Just over five years ago I was diagnosed with restless legs syndrome – my symptoms were apparently ‘typical’. The neurologist ...
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...
Medscape4d
FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion ...
Medpage Today on MSN5d
Continuous Parkinson's Disease Therapy Wins FDA Nod
AbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly ...
FiercePharma5d
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...
Badger Herald2h
Brett Favre’s testimony highlights Parkinson’s disease awareness after recent diagnosis
Tuesday, Sept. 24, former Green Bay Packer and NFL Hall of Fame quarterback Brett Favre testified before Congress. Favre was ...
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...
After rejections, AbbVie secures approval for Parkinson’s drug
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired ...
McKnight's Long-Term Care News3d
A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...